Mainz Biomed Appoints Robert Liscouski as Chairman and Renames to Quantum Cyber
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 11 2026
0mins
Should l Buy MYNZ?
Mainz Biomed announced that Robert Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Liscouski and the change of Company name will become effective at the Company's extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on March 12, 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MYNZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MYNZ
Wall Street analysts forecast MYNZ stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.844
Low
14.00
Averages
14.00
High
14.00
Current: 0.844
Low
14.00
Averages
14.00
High
14.00
About MYNZ
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mainz Biomed to Present at Digestive Disease Week 2026
- Conference Participation: Mainz Biomed N.V. will present its poster titled 'BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA' at the 2026 Digestive Disease Week in Chicago, marking a significant advancement in cancer early detection.
- Clinical Results Confirmation: CEO Guido Baechler highlighted the team's substantial progress in confirming strong clinical results from their discovery study, indicating that their algorithm and biomarker selection can identify neoplasms in blood samples.
- Early Detection Test: The company's PancAlert product candidate portfolio focuses on an early-stage pancreatic cancer screening test based on real-time PCR multiplex detection of molecular-genetic biomarkers in blood and stool samples, showcasing its potential market value.
- Strategic Implications: By delivering a blood-based test capable of detecting early stages of disease, Mainz Biomed is making significant strides toward the elimination of pancreatic cancer, enhancing its market competitiveness while providing new hope for patients.
See More
Mainz Biomed Secures $6 Million Financing for Strategic Shift
- Financing Agreement: Mainz Biomed has entered into a $6 million securities purchase agreement with investor David Lazar, aimed at enhancing liquidity and supporting a strategic shift towards its pancreatic cancer detection program in the U.S.
- Financing Structure: The financing will be completed in two tranches of $3 million each through the issuance of convertible non-redeemable preferred stock, with the first tranche closing on February 13 and the second expected to close before April 15, subject to stockholder approvals.
- Clear Use of Funds: The company stated that net proceeds will be used to fund ongoing operations, address outstanding liabilities, and maintain operations while evaluating growth opportunities and broader strategic alternatives.
- Management Change: In connection with the financing, David Lazar has been appointed chairman of the board, and Mainz Biomed plans to focus on developing its pancreatic cancer screening business in the U.S. while considering options to sell its colorectal cancer screening assets and wind down its German subsidiary.
See More
Mainz Biomed Secures $6 Million Funding to Enhance Liquidity and Focus on Pancreatic Cancer Detection
- Funding Transaction Completed: Mainz Biomed N.V. completed a $6 million private placement on February 13, 2026, structured in two tranches of $3 million each, with the first tranche already closed and the second expected before April 15, 2026, aimed at funding ongoing operations and addressing liabilities to enhance liquidity and stability.
- Strategic Focus Transition: The company is shifting its focus to the U.S. pancreatic cancer screening program while evaluating opportunities to sell its colorectal cancer screening assets, which will significantly reduce operating costs and extend its runway, ensuring flexibility as it explores long-term growth opportunities.
- Board Changes: Following the financing, David Lazar was appointed as Chairman of the Board, stating that this funding provides critical operational support, ensuring the company can steadily advance its pancreatic screening program while exploring additional strategic options to enhance shareholder value.
- German Subsidiary Wind Down: The company is winding down its German subsidiary and is in discussions to sell its colorectal cancer assets, a move that not only helps reduce operating expenses but also allows for a concentrated focus on the more promising pancreatic cancer screening business, thereby enhancing overall market competitiveness.
See More
Mainz Biomed Launches eAArly DETECT 2 Clinical Study Covering 2,000 Patients
- Clinical Study Launch: Mainz Biomed initiates the eAArly DETECT 2 clinical study, aiming to evaluate its next-generation colorectal cancer test on approximately 2,000 average-risk patients, which will validate previous leading results and lay the groundwork for future FDA pivotal trials.
- Market Expansion: The ColoAlert® test has received registration from the UK’s MHRA and Swissmedic, marking its debut in the Swiss market and significantly enhancing Mainz Biomed's market share and influence across Europe.
- Strategic Partnerships: The strategic partnership with labor team w ag introduces ColoAlert® to the Swiss market, while collaboration with OncoVanguard8 aims to expand its reach into South America, demonstrating the company's commitment to global market expansion.
- Funding Support: Mainz Biomed's pancreatic cancer project receives public funding from Germany's ISB, covering up to 50% of total project costs, which not only enhances the project's feasibility but also reflects government endorsement of its scientific value.
See More
Mainz Biomed Integrates ColoAlert® Test into DoctorBox Platform in Germany
- Market Expansion: Mainz Biomed's ColoAlert® test has been integrated into DoctorBox, a leading digital health platform in Germany, marking a significant milestone in the company's European growth strategy and expected to greatly enhance access to early cancer detection.
- User Base: With over one million registered users and more than ten million test results, the integration of ColoAlert® will further solidify DoctorBox's leadership in digital preventive healthcare, driving business growth for Mainz Biomed.
- Innovative Collaboration: The partnership with DoctorBox not only lowers barriers to colorectal cancer screening but also enhances user engagement through at-home testing, aligning with modern healthcare service trends.
- Importance of Preventive Care: With approximately 60,000 new colorectal cancer cases diagnosed annually in Germany, the introduction of ColoAlert® provides an effective early detection solution to meet this demand, further advancing the development of personalized preventive healthcare.
See More
Mainz Biomed Partners with DoctorBox to Launch ColoAlert Test in Germany
- Market Expansion: Mainz Biomed's ColoAlert test has been added to DoctorBox's portfolio, marking a significant milestone in the company's European growth strategy and is expected to greatly enhance access to early cancer detection.
- Collaborative Advantage: By partnering with DoctorBox, Mainz Biomed can offer ColoAlert testing in home settings, lowering barriers to colorectal cancer screening and driving innovation in preventive medicine.
- User Base: With over one million registered users and more than ten million test results transmitted, DoctorBox's extensive user base will provide robust support for the promotion of ColoAlert, further enhancing the company's influence in the digital health sector.
- New Standard in Preventive Healthcare: The integration of ColoAlert into DoctorBox's digital platform will make it a cornerstone of next-generation preventive healthcare services, improving user health management experiences significantly.
See More
Mainz Biomed to Present at Digestive Disease Week 2026
- Conference Participation: Mainz Biomed N.V. will present its poster titled 'BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA' at the 2026 Digestive Disease Week in Chicago, marking a significant advancement in cancer early detection.
- Clinical Results Confirmation: CEO Guido Baechler highlighted the team's substantial progress in confirming strong clinical results from their discovery study, indicating that their algorithm and biomarker selection can identify neoplasms in blood samples.
- Early Detection Test: The company's PancAlert product candidate portfolio focuses on an early-stage pancreatic cancer screening test based on real-time PCR multiplex detection of molecular-genetic biomarkers in blood and stool samples, showcasing its potential market value.
- Strategic Implications: By delivering a blood-based test capable of detecting early stages of disease, Mainz Biomed is making significant strides toward the elimination of pancreatic cancer, enhancing its market competitiveness while providing new hope for patients.
See More
Mainz Biomed Secures $6 Million Financing for Strategic Shift
- Financing Agreement: Mainz Biomed has entered into a $6 million securities purchase agreement with investor David Lazar, aimed at enhancing liquidity and supporting a strategic shift towards its pancreatic cancer detection program in the U.S.
- Financing Structure: The financing will be completed in two tranches of $3 million each through the issuance of convertible non-redeemable preferred stock, with the first tranche closing on February 13 and the second expected to close before April 15, subject to stockholder approvals.
- Clear Use of Funds: The company stated that net proceeds will be used to fund ongoing operations, address outstanding liabilities, and maintain operations while evaluating growth opportunities and broader strategic alternatives.
- Management Change: In connection with the financing, David Lazar has been appointed chairman of the board, and Mainz Biomed plans to focus on developing its pancreatic cancer screening business in the U.S. while considering options to sell its colorectal cancer screening assets and wind down its German subsidiary.
See More
Mainz Biomed Secures $6 Million Funding to Enhance Liquidity and Focus on Pancreatic Cancer Detection
- Funding Transaction Completed: Mainz Biomed N.V. completed a $6 million private placement on February 13, 2026, structured in two tranches of $3 million each, with the first tranche already closed and the second expected before April 15, 2026, aimed at funding ongoing operations and addressing liabilities to enhance liquidity and stability.
- Strategic Focus Transition: The company is shifting its focus to the U.S. pancreatic cancer screening program while evaluating opportunities to sell its colorectal cancer screening assets, which will significantly reduce operating costs and extend its runway, ensuring flexibility as it explores long-term growth opportunities.
- Board Changes: Following the financing, David Lazar was appointed as Chairman of the Board, stating that this funding provides critical operational support, ensuring the company can steadily advance its pancreatic screening program while exploring additional strategic options to enhance shareholder value.
- German Subsidiary Wind Down: The company is winding down its German subsidiary and is in discussions to sell its colorectal cancer assets, a move that not only helps reduce operating expenses but also allows for a concentrated focus on the more promising pancreatic cancer screening business, thereby enhancing overall market competitiveness.
See More
Mainz Biomed Launches eAArly DETECT 2 Clinical Study Covering 2,000 Patients
- Clinical Study Launch: Mainz Biomed initiates the eAArly DETECT 2 clinical study, aiming to evaluate its next-generation colorectal cancer test on approximately 2,000 average-risk patients, which will validate previous leading results and lay the groundwork for future FDA pivotal trials.
- Market Expansion: The ColoAlert® test has received registration from the UK’s MHRA and Swissmedic, marking its debut in the Swiss market and significantly enhancing Mainz Biomed's market share and influence across Europe.
- Strategic Partnerships: The strategic partnership with labor team w ag introduces ColoAlert® to the Swiss market, while collaboration with OncoVanguard8 aims to expand its reach into South America, demonstrating the company's commitment to global market expansion.
- Funding Support: Mainz Biomed's pancreatic cancer project receives public funding from Germany's ISB, covering up to 50% of total project costs, which not only enhances the project's feasibility but also reflects government endorsement of its scientific value.
See More
Mainz Biomed Integrates ColoAlert® Test into DoctorBox Platform in Germany
- Market Expansion: Mainz Biomed's ColoAlert® test has been integrated into DoctorBox, a leading digital health platform in Germany, marking a significant milestone in the company's European growth strategy and expected to greatly enhance access to early cancer detection.
- User Base: With over one million registered users and more than ten million test results, the integration of ColoAlert® will further solidify DoctorBox's leadership in digital preventive healthcare, driving business growth for Mainz Biomed.
- Innovative Collaboration: The partnership with DoctorBox not only lowers barriers to colorectal cancer screening but also enhances user engagement through at-home testing, aligning with modern healthcare service trends.
- Importance of Preventive Care: With approximately 60,000 new colorectal cancer cases diagnosed annually in Germany, the introduction of ColoAlert® provides an effective early detection solution to meet this demand, further advancing the development of personalized preventive healthcare.
See More
Mainz Biomed Partners with DoctorBox to Launch ColoAlert Test in Germany
- Market Expansion: Mainz Biomed's ColoAlert test has been added to DoctorBox's portfolio, marking a significant milestone in the company's European growth strategy and is expected to greatly enhance access to early cancer detection.
- Collaborative Advantage: By partnering with DoctorBox, Mainz Biomed can offer ColoAlert testing in home settings, lowering barriers to colorectal cancer screening and driving innovation in preventive medicine.
- User Base: With over one million registered users and more than ten million test results transmitted, DoctorBox's extensive user base will provide robust support for the promotion of ColoAlert, further enhancing the company's influence in the digital health sector.
- New Standard in Preventive Healthcare: The integration of ColoAlert into DoctorBox's digital platform will make it a cornerstone of next-generation preventive healthcare services, improving user health management experiences significantly.
See More
